Johnson & Johnson (JNJ) Profit After Tax (2009 - 2026)
Johnson & Johnson (JNJ) posted Profit After Tax of $5.2 billion for Q1 2026, up 2.33% sequentially from $5.1 billion in Q4 2025, and down 52.4% YoY from $11.0 billion in Q1 2025.
Johnson & Johnson (JNJ) Profit After Tax (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Profit After Tax data on file, last reported at $5.2 billion in Q1 2026.
- Quarterly Profit After Tax fell 52.4% year-over-year to $5.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.0 billion (down 3.53% YoY) and the FY2025 annual result came in at $26.8 billion, up 90.56% from the prior year.
- Profit After Tax rose to $5.2 billion in Q1 2026 per JNJ's latest filing, from $5.1 billion in the prior quarter.
- The five-year high for Profit After Tax was $11.0 billion in Q1 2025, with the low at -$491.0 million in Q2 2023.
- Average Profit After Tax over 5 years is $4.5 billion, with a median of $4.5 billion recorded in 2022.
- Year-over-year, Profit After Tax plunged 110.74% in 2023 and soared 762.93% in 2024.
- Johnson & Johnson's Profit After Tax stood at $4.5 billion in 2022, then dropped by 9.17% to $4.0 billion in 2023, then fell by 15.26% to $3.4 billion in 2024, then jumped by 49.11% to $5.1 billion in 2025, then gained by 2.33% to $5.2 billion in 2026.
- Business Quant data shows JNJ's Profit After Tax at $5.2 billion in Q1 2026, $5.1 billion in Q4 2025, and $5.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 3.08 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.24 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 319.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 5.24 Bn |
| Dec 28, 2025 | 5.12 Bn |
| Sep 28, 2025 | 5.15 Bn |
| Jun 29, 2025 | 5.54 Bn |
| Mar 30, 2025 | 11.00 Bn |
| Dec 29, 2024 | 3.43 Bn |
| Sep 29, 2024 | 2.69 Bn |
| Jun 30, 2024 | 4.69 Bn |
| Mar 31, 2024 | 3.26 Bn |
| Dec 31, 2023 | 4.05 Bn |
| Oct 1, 2023 | 4.31 Bn |
| Jul 2, 2023 | 5.38 Bn |
| Apr 2, 2023 | -491.00 Mn |
| Jan 1, 2023 | 3.23 Bn |
| Oct 2, 2022 | 4.46 Bn |
| Jul 3, 2022 | 4.26 Bn |
| Apr 3, 2022 | 4.57 Bn |
| Oct 3, 2021 | 3.67 Bn |
| Jul 4, 2021 | 6.28 Bn |
| Apr 4, 2021 | 6.20 Bn |